For help on how to get the results you want, see our search tips.
701 results
Medicine type
Additional monitoring Remove Additional monitoring filter
Generic Remove Generic filter
Exceptional circumstances Remove Exceptional circumstances filter
Orphan medicine Remove Orphan medicine filter
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Azacitidine betapharm (updated)
azacitidine, Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute
Date of authorisation: 24/03/2020,
, Revision: 3, Authorised, Last updated: 08/12/2021
-
List item
Human medicine European public assessment report (EPAR): Marixino (previously Maruxa) (updated)
memantine hydrochloride, Alzheimer Disease
Date of authorisation: 28/04/2013,, Revision: 8, Authorised, Last updated: 08/12/2021
-
List item
Human medicine European public assessment report (EPAR): Respreeza (updated)
Human alpha1-proteinase inhibitor, Genetic Diseases, Inborn; Lung Diseases
Date of authorisation: 20/08/2015,
, Revision: 10, Authorised, Last updated: 08/12/2021
-
List item
Human medicine European public assessment report (EPAR): Glivec (updated)
imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma; Gastrointestinal Stromal Tumors; Dermatofibrosarcoma; Myelodysplastic-Myeloproliferative Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hypereosinophilic Syndrome
Date of authorisation: 07/11/2001,, Revision: 43, Authorised, Last updated: 08/12/2021
-
List item
Human medicine European public assessment report (EPAR): Imatinib Accord (updated)
imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma; Dermatofibrosarcoma; Myelodysplastic-Myeloproliferative Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hypereosinophilic Syndrome
Date of authorisation: 30/06/2013,, Revision: 17, Authorised, Last updated: 08/12/2021
-
List item
Human medicine European public assessment report (EPAR): Febuxostat Krka (updated)
febuxostat, Hyperuricemia; Gout
Date of authorisation: 28/03/2019,, Revision: 2, Authorised, Last updated: 08/12/2021
-
List item
Human medicine European public assessment report (EPAR): Repaglinide Krka (updated)
repaglinide, Diabetes Mellitus, Type 2
Date of authorisation: 03/11/2009,, Revision: 7, Authorised, Last updated: 08/12/2021
-
List item
Human medicine European public assessment report (EPAR): Enyglid (updated)
repaglinide, Diabetes Mellitus, Type 2
Date of authorisation: 13/10/2009,, Revision: 8, Authorised, Last updated: 08/12/2021
-
List item
Human medicine European public assessment report (EPAR): Temozolomide Sun (updated)
temozolomide, Glioma; Glioblastoma
Date of authorisation: 13/07/2011,, Revision: 18, Authorised, Last updated: 08/12/2021
-
List item
Human medicine European public assessment report (EPAR): Spinraza (updated)
nusinersen sodium, Muscular Atrophy, Spinal
Date of authorisation: 30/05/2017,, 
, 
, Revision: 12, Authorised, Last updated: 08/12/2021
-
List item
Human medicine European public assessment report (EPAR): Pregabalin Sandoz (updated)
pregabalin, Anxiety Disorders; Neuralgia; Epilepsy
Date of authorisation: 19/06/2015,, Revision: 9, Authorised, Last updated: 08/12/2021
-
List item
Human medicine European public assessment report (EPAR): Calquence (updated)
Acalabrutinib, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 05/11/2020,, Revision: 3, Authorised, Last updated: 08/12/2021
-
List item
Human medicine European public assessment report (EPAR): Capecitabine Accord (updated)
capecitabine, Colonic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Stomach Neoplasms
Date of authorisation: 20/04/2012,
, , Revision: 15, Authorised, Last updated: 08/12/2021
-
List item
Human medicine European public assessment report (EPAR): Verkazia (updated)
ciclosporin, Conjunctivitis; Keratitis
Date of authorisation: 06/07/2018,, , Revision: 5, Authorised, Last updated: 08/12/2021
-
List item
Human medicine European public assessment report (EPAR): Hemlibra (updated)
Emicizumab, Hemophilia A
Date of authorisation: 23/02/2018,, , Revision: 9, Authorised, Last updated: 08/12/2021
-
List item
Human medicine European public assessment report (EPAR): Abecma (updated)
idecabtagene vicleucel, Multiple Myeloma; Neoplasms; Cancer; Neoplasms, Plasma Cell; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Infectious Mononucleosis; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases
Date of authorisation: 18/08/2021,, , 
, Revision: 2, Authorised, Last updated: 08/12/2021
-
List item
Human medicine European public assessment report (EPAR): Aripiprazole Accord (updated)
aripiprazole, Schizophrenia; Bipolar Disorder
Date of authorisation: 15/11/2015,, Revision: 13, Authorised, Last updated: 08/12/2021
-
List item
Human medicine European public assessment report (EPAR): Pregabalin Accord (updated)
pregabalin, Anxiety Disorders; Epilepsy
Date of authorisation: 28/08/2015,, Revision: 10, Authorised, Last updated: 08/12/2021
-
List item
Human medicine European public assessment report (EPAR): Inrebic (updated)
fedratinib dihydrochloride monohydrate, Myeloproliferative Disorders; Primary Myelofibrosis
Date of authorisation: 08/02/2021,, , Revision: 3, Authorised, Last updated: 08/12/2021
-
List item
Human medicine European public assessment report (EPAR): Zercepac (updated)
trastuzumab, Breast Neoplasms; Stomach Neoplasms
Date of authorisation: 27/07/2020,, 
, Revision: 6, Authorised, Last updated: 08/12/2021
-
List item
Human medicine European public assessment report (EPAR): Ebilfumin (updated)
oseltamivir, Influenza, Human
Date of authorisation: 22/05/2014,, Revision: 14, Authorised, Last updated: 08/12/2021
-
List item
Human medicine European public assessment report (EPAR): Cresemba (updated)
isavuconazole, Aspergillosis
Date of authorisation: 15/10/2015,, Revision: 13, Authorised, Last updated: 07/12/2021
-
List item
Human medicine European public assessment report (EPAR): Talzenna (updated)
talazoparib, Breast Neoplasms
Date of authorisation: 20/06/2019,, Revision: 6, Authorised, Last updated: 07/12/2021
-
List item
Human medicine European public assessment report (EPAR): Miglustat Gen.Orph (updated)
miglustat, Gaucher Disease
Date of authorisation: 09/11/2017,, Revision: 7, Authorised, Last updated: 07/12/2021
-
List item
Human medicine European public assessment report (EPAR): Mayzent (updated)
Siponimod fumaric acid, Multiple Sclerosis, Relapsing-Remitting
Date of authorisation: 13/01/2020,, Revision: 6, Authorised, Last updated: 07/12/2021